Aridis Pharmaceuticals 2023 Q1 Investor Presentation

Late-stage clinical biotech company developing first-in-class respiratory therapeutics, including two Phase 3 assets (AR-301 for acute pneumonia treatment and AR-320 for prevention) with ~$1 billion market opportunities. Presentation includes clinical data readouts and company overview with experienced management team.